ImmuCell (ICCC) 10-Q 12 May 15 2015 Q1 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	3 Months Ended
	Mar. 31, 2015	7-May-15
Document And Entity Information [Abstract]
Entity Registrant Name	IMMUCELL CORP /DE/
Entity Central Index Key	811641
Current Fiscal Year End Date	-19
Entity Filer Category	Smaller Reporting Company
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	31-Mar-15
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2015
Entity Common Stock, Shares Outstanding		3,029,034

Balance_Sheets_Unaudited

Balance Sheets (Unaudited) (USD $)	Mar. 31, 2015	Dec. 31, 2014
CURRENT ASSETS:
Cash and cash equivalents	$2,470,088	$850,028
Short-term investments	1,740,000	2,489,000
Accounts receivable, net	754,854	1,005,292
Inventory	578,663	945,755
Prepaid expenses and other assets	178,621	148,399
Current portion of deferred tax asset	17,673	30,463
Total current assets	5,739,899	5,468,937
PROPERTY, PLANT AND EQUIPMENT, net	4,558,596	3,837,647
LONG-TERM PORTION OF DEFERRED TAX ASSET	913,003	1,230,340
LONG-TERM INVESTMENTS	0	496,000
OTHER ASSETS, net	18,210	18,930
TOTAL ASSETS	11,229,708	11,051,854
CURRENT LIABILITIES:
Accounts payable and accrued expenses	587,186	851,677
Current portion of bank debt	115,368	150,382
Deferred revenue	6,690	6,690
Total current liabilities	709,244	1,008,749
LONG-TERM LIABILITIES:
Long-term portion of bank debt	731,877	745,920
Interest rate swap	45,315	38,817
Total long-term liabilities	777,192	784,737
TOTAL LIABILITIES	1,486,436	1,793,486
STOCKHOLDERS' EQUITY:
Common stock, $0.10 par value per share, 8,000,000 shares authorized, 3,261,148 shares issued as of March 31, 2015 and December 31, 2014	326,115	326,115
Capital in excess of par value	10,049,845	10,042,305
Accumulated deficit	-95,485	-574,567
Treasury stock, at cost, 233,114 and 234,114 shares as of March 31, 2015 and December 31, 2014, respectively	-509,966	-512,154
Accumulated other comprehensive loss	-27,237	-23,331
Total stockholders' equity	9,743,272	9,258,368
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$11,229,708	$11,051,854

Balance_Sheets_Unaudited_Paren

Balance Sheets (Unaudited) (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Statement Of Financial Position [Abstract]
Common stock, shares authorized	8,000,000	8,000,000
Common stock, par value (in dollars per share)	$0.10	$0.10
Common stock, shares issued	3,261,148	3,261,148
Treasury stock, shares	233,114	234,114

Statements_of_Operations_Unaud

Statements of Operations (Unaudited) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Income Statement [Abstract]
Product sales	$3,101,491	$2,081,752
Cost of goods sold	1,250,566	931,857
Gross margin	1,850,925	1,149,895
Sales and marketing expenses	388,903	285,305
Product development expenses	330,665	594,209
Administrative expenses	311,305	257,820
Operating expenses	1,030,873	1,137,334
NET OPERATING INCOME	820,052	12,561
Other expenses, net	5,450	11,407
INCOME BEFORE INCOME TAXES	814,602	1,154
Income tax expense	335,520	14,489
NET INCOME (LOSS)	$479,082	($13,335)
Weighted average common shares outstanding:
Basic	3,027,345	3,026,901
Diluted	3,143,576	3,026,901
NET INCOME (LOSS) PER SHARE:
Basic	$0.16	$0
Diluted	$0.15	$0

Statements_of_Comprehensive_In

Statements of Comprehensive Income (Loss) (Unaudited) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Statement of Other Comprehensive Income [Abstract]
Net income (loss)	$479,082	($13,335)
Other comprehensive (loss):
Interest rate swap, before taxes	-6,498	-2,342
Income tax applicable to interest rate swap	2,592	934
Other comprehensive (loss), net of taxes	-3,906	-1,408
Total comprehensive income (loss)	$475,176	($14,743)

Statements_of_Stockholders_Equ

Statements of Stockholders' Equity (Unaudited) (USD $)	Total	Common Stock	Capital in Excess of Par Value	Accumulated Deficit	Treasury Stock	Accumulated Other Comprehensive (Loss)
Balance at Dec. 31, 2013	$9,395,869	$326,115	$10,011,339	($407,408)	($514,341)	($19,836)
Balance (in shares) at Dec. 31, 2013		3,261,148			235,114
Net income (loss)	-13,335	0	0	-13,335	0	0
Other comprehensive (loss), net of taxes	-1,408	0	0	0	0	-1,408
Exercise of stock options	3,150	0	962	0	2,188	0
Exercise of stock options, Shares		0			-1,000
Stock-based compensation	7,358	0	7,358	0	0	0
Balance at Mar. 31, 2014	9,391,634	326,115	10,019,659	-420,743	-512,153	-21,244
Balance (in shares) at Mar. 31, 2014		3,261,148			234,114
Balance at Dec. 31, 2014	9,258,368	326,115	10,042,305	-574,567	-512,154	-23,331
Balance (in shares) at Dec. 31, 2014		3,261,148			234,114
Net income (loss)	479,082	0	0	479,082	0	0
Other comprehensive (loss), net of taxes	-3,906	0	0	0	0	-3,906
Exercise of stock options	5,250	0	3,062	0	2,188	0
Exercise of stock options, Shares		0			-1,000
Stock-based compensation	4,478	0	4,478	0	0	0
Balance at Mar. 31, 2015	$9,743,272	$326,115	$10,049,845	($95,485)	($509,966)	($27,237)
Balance (in shares) at Mar. 31, 2015		3,261,148			233,114

Statements_of_Stockholders_Equ1

Statements of Stockholders' Equity (Unaudited) (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014	Mar. 31, 2014
Statement Of Stockholders Equity [Abstract]
Common Stock, Par Or Stated Value Per Share	$0.10	$0.10	$0.10

Statements_of_Cash_Flows_Unaud

Statements of Cash Flows (Unaudited) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss)	$479,082	($13,335)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation	115,664	112,362
Amortization	720	719
Deferred income taxes	332,718	14,236
Stock-based compensation	4,478	7,358
Gain on disposal of fixed assets	-5,306	0
Changes in:
Receivables	250,438	-88,616
Inventory	367,092	259,183
Prepaid expenses and other assets	-30,222	1,028
Accounts payable and accrued expenses	-112,903	11,904
Net cash provided by operating activities	1,401,761	304,839
CASH FLOWS FROM INVESTING ACTIVITIES :
Purchase of property, plant and equipment	-988,459	-44,853
Maturities of investments	1,245,000	1,494,000
Purchases of investments	0	-1,741,000
Proceeds from sale of fixed assets	5,565	0
Net cash provided by (used for) investing activities	262,106	-291,853
CASH FLOWS FROM FINANCING ACTIVITIES:
Debt principal repayments	-49,057	-46,790
Proceeds from exercise of stock options	5,250	3,150
Net cash (used for) financing activities	-43,807	-43,640
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	1,620,060	-30,654
BEGINNING CASH AND CASH EQUIVALENTS	850,028	2,270,385
ENDING CASH AND CASH EQUIVALENTS	2,470,088	2,239,731
INCOME TAXES PAID	2,800	252
INTEREST EXPENSE PAID	13,050	15,175
NON-CASH ACTIVITIES:
Change in capital expenditures included in accounts payable and accrued expenses	-151,588	191,862
Net change in fair value of interest rate swap	$3,906	$1,408

Business_Operations

Business Operations	3 Months Ended
	Mar. 31, 2015
Business operations [Abstract]
BUSINESS OPERATIONS	1.           BUSINESS OPERATIONS
	ImmuCell Corporation (the Company) is a growing animal health company whose purpose is to create scientifically-proven and practical products that result in a measurable economic impact on animal health and productivity in the dairy and beef industries. The Company was originally incorporated in Maine in 1982 and reincorporated in Delaware in 1987, in conjunction with its initial public offering of common stock. The Company has developed products that provide significant, immediate immunity to newborn dairy and beef cattle and is in the late stages of developing a new product that addresses mastitis, the most significant cause of economic loss to the dairy industry. The Company is subject to certain risks associated with its stage of development including dependence on key individuals, competition from other larger companies, the successful sale of existing products and the development and acquisition of additional commercially viable products with appropriate regulatory approvals, where applicable. These and other risks to our company are further detailed under PART II: OTHER INFORMATION, ITEM 1A – RISK FACTORS.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2015
Summary of Significant Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	2.           SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	(a)          Basis of presentation
	We have prepared the accompanying unaudited financial statements reflecting all adjustments, all of which are of a normal recurring nature, that are, in our opinion, necessary in order to ensure that the financial statements are not misleading. We follow accounting standards set by the Financial Accounting Standards Board (FASB). The FASB sets generally accepted accounting principles (GAAP) that we follow to ensure we consistently report our financial condition, results of operations, earnings per share and cash flows. References to GAAP in these footnotes are to the FASB Accounting Standards Codification™ (Codification). Certain prior year accounts have been reclassified to conform with the 2015 financial statement presentation. Certain information and footnote disclosures normally included in the annual financial statements have been condensed or omitted. Accordingly, we believe that although the disclosures are adequate to ensure that the information presented is not misleading, these financial statements should be read in conjunction with the financial statements for the year ended December 31, 2014 and the notes thereto, contained in our Annual Report on Form 10-K as filed with the Securities and Exchange Commission (SEC).
	(b)          Cash, Cash Equivalents and Short-Term Investments
	We consider all highly liquid investment instruments that mature within three months of their purchase dates to be cash equivalents. Cash equivalents are principally invested in securities backed by the U.S. government. Certain cash balances in excess of Federal Deposit Insurance Corporation (FDIC) limits of $250,000 per financial institution per depositor are maintained in money market accounts at financial institutions that are secured, in part, by the Securities Investor Protection Corporation. Amounts in excess of these FDIC limits per bank that are not invested in securities backed by the U.S. government aggregated $1,969,788 and $566,637 as of March 31, 2015 and December 31, 2014, respectively. Short-term investments are classified as held to maturity and are comprised principally of certificates of deposit that mature in more than three months from their purchase dates and not more than twelve months from the balance sheet date and are held at different financial institutions that are insured by the FDIC, within the FDIC limits per financial institution. See Note 3.
	(c)          Inventory
	Inventory includes raw materials, work-in-process and finished goods and is recorded at the lower of cost, on the first-in, first-out method, or market (net realizable value). Work-in-process and finished goods inventories include materials, labor and manufacturing overhead. See Note 4.
	(d)          Trade Receivables
	Trade receivables are carried at the original invoice amount less an estimate made for doubtful collection. Management determines the allowance for doubtful accounts on a monthly basis by identifying troubled accounts and by using historical experience applied to an aging of accounts. Trade receivables are written off when deemed uncollectible. Recoveries of trade receivables previously written off are recorded as income when received. A trade receivable is considered to be past due if any portion of the receivable balance is outstanding for more than 30 days. Interest is charged on past due trade receivables. See Note 5.
	(e)          Property, Plant and Equipment
	We depreciate property, plant and equipment on the straight-line method by charges to operations in amounts estimated to expense the cost of the assets from the date they are first put into service to the end of the estimated useful lives of the assets. The cost of our building (which was acquired in 1993) and the 2001 and 2007 additions thereto are being depreciated through 2023. We are depreciating the building addition that was completed during the first quarter of 2015 over twenty-five years. Related building improvements are depreciated over ten year periods. Large and durable fixed assets are depreciated over their useful lives that are generally estimated to be five to ten years. Other fixed assets and computer equipment are depreciated over their useful lives that are generally estimated to be five and three years, respectively. See Note 7.
	(f)          Intangible Assets
	We amortize intangible assets on the straight-line method by charges to operations in amounts estimated to expense the cost of the assets from the date they are first put into service to the end of the estimated useful lives of the assets. In connection with certain credit facilities entered into during the third quarter of 2010, we incurred debt issue costs of $26,489, which costs are being amortized to other expenses, net over the terms of the credit facilities. See Notes 6 and 9.
	We continually assess the realizability of these assets in accordance with the impairment provisions of Codification Topic 360, Accounting for the Impairment or Disposal of Long-Lived Assets. If an impairment review is triggered, we evaluate the carrying value of long-lived assets by determining if impairment exists based on estimated undiscounted future cash flows over the remaining useful life of the assets and comparing that value to the carrying value of the assets. If the carrying value of the asset is greater than the estimated future cash flows, the asset is written down to its estimated fair value. The cash flow estimates that are used contain our best estimates, using appropriate and customary assumptions and projections at the time. We also review the estimated useful life of intangible assets at the end of each reporting period, making any necessary adjustments.
	(g)          Disclosure of Fair Value of Financial Instruments and Concentration of Risk
	Financial instruments consist mainly of cash, cash equivalents, short-term investments, long-term investments, accounts receivable, accounts payable, bank debt and an interest rate swap. Financial instruments that potentially subject the Company to concentrations of credit risk are principally cash, cash equivalents, short-term investments, long-term investments and accounts receivable. We make short-term and long-term investments in financial instruments that are insured by the FDIC. We account for fair value measurements in accordance with Codification Topic 820, Fair Value Measurements and Disclosures, which defines fair value, establishes a framework for measuring fair value and requires additional disclosures about fair value measurements. The estimated fair value of cash, cash equivalents, short-term investments, long-term investments, accounts receivable and accounts payable approximate their carrying value due to their short maturities. The estimated fair value of bank debt approximates its carrying value because the interest rates are variable. The interest rate swap is carried at fair value. See Note 9.
	Concentration of credit risk with respect to accounts receivable is principally limited to certain customers to whom we make substantial sales. To reduce risk, we routinely assess the financial strength of our customers and, as a consequence, believe that our accounts receivable credit risk exposure is limited. We maintain an allowance for potential credit losses, but historically we have not experienced significant credit losses related to an individual customer or groups of customers in any particular industry or geographic area.
	We believe that supplies and raw materials for the production of our products are available from more than one vendor or farm. Our policy is to maintain more than one source of supply for the components used in our products. However, there is a risk that we could have difficulty in efficiently acquiring essential supplies.
	(h)          Interest Rate Swap Agreement
	All derivatives are recognized on the balance sheet at their fair value. We entered into an interest rate swap agreement in 2010. On the date the agreement was entered into, we designated the derivative as a hedge of the variability of cash flows to be paid related to our long-term debt. The agreement has been determined to be highly effective in hedging the variability of identified cash flows, so changes in the fair market value of the interest rate swap agreement are recorded as comprehensive (loss) income, until earnings are affected by the variability of cash flows (e.g. when periodic settlements on a variable-rate asset or liability are recorded in earnings). We formally documented the relationship between the interest rate swap agreement and the related hedged items. We also formally assess, both at this interest rate swap agreement’s inception and on an ongoing basis, whether the agreement is highly effective in offsetting changes in cash flow of hedged items. See Note 9.
	(i)          Revenue Recognition
	We recognize revenue in accordance with Staff Accounting Bulletin (SAB) No. 104, “Revenue Recognition”, which supersedes SAB No. 101, “Revenue Recognition in Financial Statements”. SAB No. 104 requires that four criteria are met before revenue is recognized. These include i) persuasive evidence that an arrangement exists, ii) delivery has occurred or services have been rendered, iii) the seller’s price is fixed and determinable and iv) collectability is reasonably assured. We recognize revenue at the time of shipment (including to distributors) for substantially all products, as title and risk of loss pass to the customer on delivery to the common carrier after concluding that collectability is reasonably assured. We recognize service revenue at the time the service is performed.
	(j)          Expense Recognition
	Advertising costs are expensed when incurred, which is generally during the month in which the advertisement is published. Advertising expenses amounted to $29,221 and $18,789 during the three-month periods ended March 31, 2015 and 2014, respectively. All product development expenses are expensed as incurred, as are all related patent costs.
	(k)         Income Taxes
	We account for income taxes in accordance with Codification Topic 740, Income Taxes, which requires that we recognize a current tax liability or asset for current taxes payable or refundable and a deferred tax liability or asset for the estimated future tax effects of temporary differences and carryforwards to the extent they are realizable. We believe it is more likely than not that the deferred tax assets will be realized through future taxable income and future tax effects of temporary differences between book income and taxable income. Accordingly, we have not established a valuation allowance for the deferred tax assets. Codification Topic 740-10 clarifies the accounting for income taxes by prescribing a minimum recognition threshold that a tax position must meet before being recognized in the financial statements. In the ordinary course of business, there are transactions and calculations where the ultimate tax outcome is uncertain. In addition, we are subject to periodic audits and examinations by the Internal Revenue Service and other taxing authorities. We have evaluated the positions taken on our filed tax returns. We have concluded that no uncertain tax positions exist as of March 31, 2015. Although we believe that our estimates are reasonable, actual results could differ from these estimates. See Note 11.
	(l)          Stock-Based Compensation
	We account for stock-based compensation in accordance with Codification Topic 718, Compensation-Stock Compensation, which generally requires us to recognize non-cash compensation expense for stock-based payments using the fair-value-based method. The fair value of each stock option grant has been estimated on the date of grant using the Black-Scholes option pricing model. Accordingly, we recorded $4,478 and $7,358 of compensation expense pertaining to stock-based compensation, which resulted in a decrease to income before income taxes of less than $0.01 per share during the three-month periods ended March 31, 2015 and 2014, respectively. Codification Topic 718 requires us to reflect gross tax savings resulting from tax deductions in excess of expense reflected in our financial statements as a financing cash flow.
	(m)        Net Income (Loss) Per Common Share
	Net Income (Loss) per common share has been computed in accordance with Codification Topic 260-10, Earnings Per Share. The basic Net Income per share has been computed by dividing Net Income by the weighted average number of common shares outstanding during this period. Diluted Net Income per share has been computed by dividing Net Income by the weighted average number of shares outstanding during the period plus all outstanding stock options with an exercise price that is less than the average market price of the common stock during the period less the number of shares that could have been repurchased at this average market price with the proceeds from the hypothetical stock option exercises. The Net (Loss) per common share in 2014 has been computed by dividing the Net (Loss) by the weighted average number of common shares outstanding during the period, without giving consideration to outstanding stock options because the impact would be anti-dilutive.
		Three-Month Period
		Ended March 31,
		2015		2014
	Weighted average number of shares outstanding		3,027,345		3,026,901
	Effect of dilutive stock options		116,231		0
	Diluted number of shares outstanding		3,143,576		3,026,901
	Outstanding stock options not included in the calculation
	because the effect would be anti-dilutive		4,000		246,000
	(n)          Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual amounts could differ from those estimates.
	(o)          New Accounting Pronouncement
	In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (ASU 2014-09), which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. ASU 2014-09 is effective for the Company on January 1, 2017. Early application is not permitted. ASU 2014-09 permits the use of either the retrospective or cumulative effect transition method. We have evaluated the effect that ASU 2014-09 would have on our financial statements and related disclosures. We expect that ASU 2014-09 will have no significant effect on our ongoing financial reporting, but we continue to evaluate this pending accounting standard.

Cash_Cash_Equivalents_ShortTer

Cash, Cash Equivalents, Short-Term Investments and Long-Term Investments	3 Months Ended
	Mar. 31, 2015
Cash, Cash Equivalents, Short-Term Investments and Long-Term Investments [Abstract]
CASH, CASH EQUIVALENTS, SHORT-TERM INVESTMENTS AND LONG-TERM INVESTMENTS	3.            CASH, CASH EQUIVALENTS, SHORT-TERM INVESTMENTS AND LONG-TERM INVESTMENTS
	Cash, cash equivalents, short-term investments and long-term investments consisted of the following:
		As of		As of		Increase
		31-Mar-15		December 31, 2014		(Decrease)
	Cash and cash equivalents	$	2,470,088	$	850,028	$	1,620,060
	Short-term investments		1,740,000		2,489,000		(749,000	)
	Subtotal		4,210,088		3,339,028		871,060
	Long-term investments		0		496,000		(496,000	)
	Total	$	4,210,088	$	3,835,028	$	375,060

Inventory

Inventory	3 Months Ended
	Mar. 31, 2015
Inventory [Abstract]
INVENTORY	4.           INVENTORY
	Inventory consisted of the following:
		As of		As of		Increase
		31-Mar-15		December 31, 2014		(Decrease)
	Raw materials	$	314,317	$	306,444	$	7,873
	Work-in-process		221,645		355,745		(134,100	)
	Finished goods		42,701		283,566		(240,865	)
	Total	$	578,663	$	945,755	($	367,092	)

Accounts_Receivable

Accounts Receivable	3 Months Ended
	Mar. 31, 2015
Accounts Receivable[Abstract]
ACCOUNTS RECEIVABLE	5.           ACCOUNTS RECEIVABLE
	Accounts receivable consisted of the following:
		As of			As of			(Decrease)
		31-Mar-15			December 31, 2014
	Trade accounts receivable, gross	$	755,221		$	1,004,990		($	249,769	)
	Accumulated allowance for bad debt and product returns		(16,637	)		(16,194	)		(443	)
	Trade accounts receivable, net		738,584			988,796			(250,212	)
	Other receivables		16,270			16,496			(226	)
	Accounts receivable, net	$	754,854		$	1,005,292		($	250,438	)

Prepaid_Expenses_and_Other_Ass

Prepaid Expenses and Other Assets	3 Months Ended
	Mar. 31, 2015
Prepaid Expenses and Other Assets [Abstract]
PREPAID EXPENSES AND OTHER ASSETS	6.           PREPAID EXPENSES AND OTHER ASSETS
	Prepaid expenses and other assets consisted of the following:
		As of			As of			Increase
		31-Mar-15			December 31, 2014			(Decrease)
	Prepaid expenses and other assets	$	163,341		$	133,119		$	30,222
	Security deposits		15,280			15,280			0
	Current subtotal		178,621			148,399			30,222
	Debt issue costs		26,489			26,489			0
	Accumulated amortization of debt issue costs		(17,199	)		(16,479	)		(720	)
	Security deposits		8,920			8,920			0
	Long-term subtotal		18,210			18,930			(720	)
	Total	$	196,831		$	167,329		$	29,502

Property_Plant_And_Equipment

Property, Plant And Equipment	3 Months Ended
	Mar. 31, 2015
Property, Plant and Equipment [Abstract]
PROPERTY, PLANT AND EQUIPMENT	7.           PROPERTY, PLANT AND EQUIPMENT
	Property, plant and equipment consisted of the following, at cost:
		As of			As of			Increase
		31-Mar-15			December 31, 2014			(Decrease)
	Laboratory and manufacturing equipment	$	3,598,697		$	3,522,465		$	76,232
	Building and improvements		4,418,964			2,969,891			1,449,073
	Office furniture and equipment		475,147			470,607			4,540
	Construction in progress(1)		530,526			1,270,672			(740,146	)
	Land		50,000			50,000			0
	Property, plant and equipment, gross		9,073,334			8,283,635			789,699
	Accumulated depreciation		(4,514,738	)		(4,445,988	)		(68,750	)
	Property, plant and equipment, net	$	4,558,596		$	3,837,647		$	720,949
	(1) As of December 31, 2014, construction in progress consisted of a building addition that was completed during the first quarter of 2015. As of March 31, 2015, construction in progress consisted principally of payments towards new manufacturing equipment.

Accounts_Payable_and_Accrued_E

Accounts Payable and Accrued Expenses	3 Months Ended
	Mar. 31, 2015
Accounts Payable and Accrued Expenses [Abstract]
ACCOUNTS PAYABLE AND ACCRUED EXPENSES	8.           ACCOUNTS PAYABLE AND ACCRUED EXPENSES
	Accounts payable and accrued expenses consisted of the following:
		As of		As of		(Decrease)
		31-Mar-15		December 31, 2014
	Accounts payable – capital	$	99,795	$	251,383	($	151,588	)
	Accounts payable – trade		203,972		204,810		(838	)
	Accrued payroll		124,867		145,176		(20,309	)
	Accrued clinical studies		68,428		131,945		(63,517	)
	Accrued professional fees		32,737		42,250		(9,513	)
	Accrued other		57,387		76,113		(18,726	)
	Total	$	587,186	$	851,677	($	264,491	)

Bank_Debt

Bank Debt	3 Months Ended
	Mar. 31, 2015
Bank Debt [Abstract]
BANK DEBT	9.           BANK DEBT
	During the third quarter of 2010, we agreed to terms of certain credit facilities with TD Bank, N.A. (a wholly owned subsidiary of TD Financial Group, which is a multinational bank with approximately $944 billion in assets and over 22 million clients worldwide) aggregating up to approximately $2,100,000, which are secured by substantially all of our assets. These credit facilities are comprised of a $1,000,000 ten-year mortgage loan, a $600,000 fifty-four month note and a $500,000 line of credit, which is renewable annually. Proceeds from the $1,000,000 mortgage were received during the third quarter of 2010. Based on a 15-year amortization schedule, a balloon principal payment of $451,885 will be due in the third quarter of 2020. We hedged our interest rate exposure on this mortgage loan with an interest rate swap agreement that effectively converted a floating interest rate based on the London Interbank Offered Rate (LIBOR) of 3.43% as of March 31, 2015 to the fixed rate of 6.04%. All derivatives are recognized on the balance sheet at their fair value. The agreement has been determined to be highly effective in hedging the variability of the identified cash flows and has been designated as a cash flow hedge of the variability in the hedged interest payments. Changes in the fair value of the interest rate swap agreement are recorded in other comprehensive income (loss), net of taxes. The original notional amount of the interest rate swap agreement of $1,000,000 amortizes in accordance with the amortization of the mortgage loan. The notional amount of the interest rate swap was $786,719 as of March 31, 2015. Payments required by the interest rate swap totaled $5,219 and $5,566 during the three-month periods ended March 31, 2015 and 2014, respectively. As the result of our decision to hedge this interest rate risk, we recorded other comprehensive (loss), net of taxes, in the amount of ($3,906), and ($1,408) during the three-month periods ended March 31, 2015 and 2014, respectively, which reflects the change in fair value of the interest rate swap (liability) asset, net of taxes. The fair value of the interest rate swap has been determined using observable market-based inputs or unobservable inputs that are corroborated by market data. Accordingly, the interest rate swap is classified as level 2 within the fair value hierarchy provided in Codification Topic 820, Fair Value Measurements and Disclosures. Proceeds from the $600,000 note were received during the first quarter of 2011. Interest on the note is variable at the higher of 4.25% per annum or the LIBOR plus 3.25% per annum. As of March 31, 2015, the effective interest rate on this note was 4.25%. The $500,000 line of credit is available as needed and has been extended through May 31, 2016 and is renewable annually thereafter. The line of credit was unused as of March 31, 2015 and December 31, 2014. Interest on any borrowings against the line of credit would be variable at the higher of 4.25% per annum or the LIBOR plus 3.5% per annum. These credit facilities are subject to certain financial covenants. We are in compliance with all applicable covenants as of March 31, 2015. Principal payments due under debt outstanding as of March 31, 2015 are reflected in the following table by the year that payments are due:
	Period	$1,000,000		$600,000		Total
		mortgage		note
	Nine months ending December 31, 2015	$	40,799	$	60,526	$	101,325
	Year ending December 31, 2016		57,384		0		57,384
	Year ending December 31, 2017		61,056		0		61,056
	Year ending December 31, 2018		64,876		0		64,876
	Year ending December 31, 2019		68,908		0		68,908
	After December 31, 2019		493,696		0		493,696
	Total	$	786,719	$	60,526	$	847,245

Other_Expenses_Net

Other Expenses, Net	3 Months Ended
	Mar. 31, 2015
Other Expenses, Net [Abstract]
OTHER EXPENSES, NET	10.         OTHER EXPENSES, NET
	Other expenses, net, consisted of the following:
		Three-Month Periods
		Ended March 31,
		2015			2014
	Interest income	($	2,982	)	($	3,954	)
	Interest expense		13,071			14,962
	Debt issuance amortization		720			719
	Other (gains)		(5,359	)		(320	)
	Other expenses, net	$	5,450		$	11,407

Income_Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2015
Income Taxes [Abstract]
INCOME TAXES	11.         INCOME TAXES
	Our income tax expense aggregated $335,520 and $14,489 (amounting to 41% and 1,256% of our income before income taxes, respectively) for the three-month periods ended March 31, 2015 and 2014, respectively. Our income tax rate was unusually high during the first quarter of 2014 because the income before income taxes was very low during that period. As of December 31, 2014, we have a state net operating loss carryforward of approximately $1,858,000 that expires in 2028 through 2031, if not utilized before then, and a federal net operating loss carryforward of approximately $1,368,000 that expires in 2029 through 2031, if not utilized before then. The $965,000 licensing payment that we made during the fourth quarter of 2004 was treated as an intangible asset and is being amortized over 15 years, for tax return purposes only. Approximately $1,112,000 of our investment to produce pharmaceutical-grade Nisin for Mast Out® was expensed as incurred for our books. Included in this amount is approximately $820,000 ($65,000 during the fourth quarter of 2013 and $755,000 during the year ended December 31, 2014) that was capitalized and will be depreciated over statutory periods for tax return purposes only.
	Deferred tax assets are recognized only when it is probable that sufficient taxable income will be available in future periods against which deductible temporary differences and credits may be utilized. However, the amount of the deferred tax asset could be reduced if projected income is not achieved due to various factors, such as unfavorable business conditions. If projected income is not expected to be achieved, we would decrease the deferred tax asset to the amount that we believe can be realized.
	Net operating loss carryforwards, credits, and other tax attributes are subject to review and possible adjustment by the Internal Revenue Service. Section 382 of the Internal Revenue Code contains provisions that could place annual limitations on the future utilization of net operating loss carryforwards and credits in the event of a change in ownership of the Company, as defined.
	The Company files income tax returns in the U.S. federal jurisdiction and several state jurisdictions. With few exceptions, the Company is no longer subject to income tax examinations by tax authorities for years before 2011. We currently have no tax examinations in progress. We also have not paid additional taxes, interest or penalties as a result of tax examinations nor do we have any unrecognized tax benefits for any of the periods in the accompanying financial statements.

Commitments_and_Contingent_Lia

Commitments and Contingent Liabilities	3 Months Ended
	Mar. 31, 2015
Commitments and Contingent Liabilities [Abstract]
COMMITMENTS AND CONTINGENT LIABILITIES	12.         COMMITMENTS AND CONTINGENT LIABILITIES
	Our bylaws, as amended, in effect provide that the Company will indemnify its officers and directors to the maximum extent permitted by Delaware law. In addition, we make similar indemnity undertakings to each director through a separate indemnification agreement with that director. The maximum payment that we may be required to make under such provisions is theoretically unlimited and is impossible to determine. We maintain directors’ and officers’ liability insurance, which may provide reimbursement to the Company for payments made to, or on behalf of, officers and directors pursuant to the indemnification provisions. Our indemnification obligations were grandfathered under the provisions of Codification Topic 460, Guarantees. Accordingly, we have recorded no liability for such obligations as of March 31, 2015. Since our incorporation, we have had no occasion to make any indemnification payment to any of our officers or directors for any reason.
	As of March 31, 2015, we had committed approximately $766,794 principally related to the production of inventory and an additional $66,988 to other obligations.
	We enter into agreements with third parties in the ordinary course of business under which we are obligated to indemnify such third parties from and against various risks and losses. The precise terms of such indemnities vary with the nature of the agreement. In many cases, we limit the maximum amount of our indemnification obligations, but in some cases those obligations may be theoretically unlimited. We have not incurred material expenses in discharging any of these indemnification obligations, and based on our analysis of the nature of the risks involved, we believe that the fair value of these agreements is minimal. Accordingly, we have recorded no liabilities for such obligations as of March 31, 2015.
	The development, manufacturing and marketing of animal health care products entails an inherent risk that liability claims will be asserted against us. We feel that we have reasonable levels of liability insurance to support our operations.

Segment_and_Significant_Custom

Segment and Significant Customer Information	3 Months Ended
	Mar. 31, 2015
Segment and Significant Customer Information [Abstract]
SEGMENT AND SIGNIFICANT CUSTOMER INFORMATION	13.         SEGMENT AND SIGNIFICANT CUSTOMER INFORMATION
	We principally operate in the business segment described in Note 1. Pursuant to Codification Topic 280, Segment Reporting, we operate in one reportable business segment, that being the development, acquisition, manufacture and sale of products that improve the health and productivity of cows for the dairy and beef industries. Almost all of our internally funded product development expenses are in support of such products. The significant accounting policies of this segment are described in Note 2.
	Our primary customers for the majority of our product sales (83% and 79% for the three-month periods ended March 31, 2015 and 2014, respectively) are in the U.S. dairy and beef industries. Product sales to international customers, who are also in the dairy and beef industries, aggregated 16% and 14% of our total product sales for the three-month periods ended March 31, 2015 and 2014, respectively. Sales to significant customers that amounted to 10% or more of total product sales are detailed in the following table:
		Three-Month Periods Ended March 31,
		2015			2014
	Animal Health International, Inc.(1)		42	%		38	%
	MWI Veterinary Supply Company(2)		26	%		23	%
	Accounts receivable due from significant customers amounted to the percentages of total trade accounts receivable as detailed in the following table:
		As of			As of
		31-Mar-15			31-Dec-14
	Animal Health International, Inc.(1)		40	%		45	%
	MWI Veterinary Supply Company(2)		28	%		26	%
	(1) During May 2015, Patterson Companies, Inc. (NASDAQ: PDCO) announced its intent to aquire Animal Health International, Inc.
	(2) During March 2015, AmerisourceBergen Corporation (NYSE: ABC) acquired MWI Veterinary Supply Company.

Related_Party_Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2015
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	14.          RELATED PARTY TRANSACTIONS
	Dr. David S. Tomsche (Chair of our Board of Directors) is a controlling owner of Leedstone Inc. (formerly Stearns Veterinary Outlet, Inc.), a domestic distributor of ImmuCell products (First Defense®, Wipe Out® Dairy Wipes, and CMT) and of J-t Enterprises of Melrose, Inc., an exporter. His affiliated companies purchased $192,642 and $125,768 of products from ImmuCell during the three-month periods ended March 31, 2015 and 2014, respectively, on terms consistent with those offered to other distributors of similar status. We made marketing-related payments of $1,272 and $4,405 to these affiliate companies during the three-month periods ended March 31, 2015 and 2014, respectively. Our accounts receivable (subject to standard and customary payment terms) due from these affiliated companies aggregated $31,226 and $18,796 as of March 31, 2015 and December 31, 2014, respectively.

Employee_Benefits

Employee Benefits	3 Months Ended
	Mar. 31, 2015
Employee Benefits [Abstract]
EMPLOYEE BENEFITS	15.         EMPLOYEE BENEFITS
	We have a 401(k) savings plan (the Plan) in which all employees completing one month of service with the Company are eligible to participate. Participants may contribute up to the maximum amount allowed by the Internal Revenue Service. Since August 2012 we have matched 100% of the first 3% of each employee’s salary that is contributed to the Plan and 50% of the next 2% of each employee’s salary that is contributed to the Plan. Under this matching plan, we paid $16,726 and $16,167 into the plan for the three-month periods ended March 31, 2015 and 2014, respectively.

Subsequent_Events

Subsequent Events	3 Months Ended
	Mar. 31, 2015
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	16.         SUBSEQUENT EVENTS
	We have adopted the disclosure provisions of Codification Topic 855-10-50-1, Subsequent Events, which provides guidance to establish general standards of accounting for and disclosures of events that occur after the balance sheet date but before financial statements are issued. Entities are required to disclose the date through which subsequent events were evaluated as well as the rationale for why that date was selected. This disclosure should alert all users of financial statements that an entity has not evaluated subsequent events after that date in the set of financial statements being presented. Codification Topic 855-10-50-1 requires additional disclosures only, and therefore did not have an impact on our financial condition, results of operations, earnings per share or cash flows. Public entities must evaluate subsequent events through the date that financial statements are issued. Accordingly, we have evaluated subsequent events through the time of filing on May 12, 2015, the date we have issued this Quarterly Report on Form 10-Q.
	During April 2015, we amended our Common Stock Rights Plan by removing a provision that prevented a new group of directors elected following the emergence of an Acquiring Person (an owner of more than 20% of our stock) from controlling the Rights Plan by maintaining exclusive authority over the Rights Plan with pre-existing directors. We did this because subsequent to the adoption of the Rights Plan in 1995, such provisions have come to be viewed with disfavor by Delaware courts.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2015
Summary of Significant Accounting Policies [Abstract]
Basis of presentation	(a)          Basis of presentation
	We have prepared the accompanying unaudited financial statements reflecting all adjustments, all of which are of a normal recurring nature, that are, in our opinion, necessary in order to ensure that the financial statements are not misleading. We follow accounting standards set by the Financial Accounting Standards Board (FASB). The FASB sets generally accepted accounting principles (GAAP) that we follow to ensure we consistently report our financial condition, results of operations, earnings per share and cash flows. References to GAAP in these footnotes are to the FASB Accounting Standards Codification™ (Codification). Certain prior year accounts have been reclassified to conform with the 2015 financial statement presentation. Certain information and footnote disclosures normally included in the annual financial statements have been condensed or omitted. Accordingly, we believe that although the disclosures are adequate to ensure that the information presented is not misleading, these financial statements should be read in conjunction with the financial statements for the year ended December 31, 2014 and the notes thereto, contained in our Annual Report on Form 10-K as filed with the Securities and Exchange Commission (SEC).
Cash, Cash Equivalents and Short-Term Investments	(b)          Cash, Cash Equivalents and Short-Term Investments
	We consider all highly liquid investment instruments that mature within three months of their purchase dates to be cash equivalents. Cash equivalents are principally invested in securities backed by the U.S. government. Certain cash balances in excess of Federal Deposit Insurance Corporation (FDIC) limits of $250,000 per financial institution per depositor are maintained in money market accounts at financial institutions that are secured, in part, by the Securities Investor Protection Corporation. Amounts in excess of these FDIC limits per bank that are not invested in securities backed by the U.S. government aggregated $1,969,788 and $566,637 as of March 31, 2015 and December 31, 2014, respectively. Short-term investments are classified as held to maturity and are comprised principally of certificates of deposit that mature in more than three months from their purchase dates and not more than twelve months from the balance sheet date and are held at different financial institutions that are insured by the FDIC, within the FDIC limits per financial institution. See Note 3.
Inventory	(c)          Inventory
	Inventory includes raw materials, work-in-process and finished goods and is recorded at the lower of cost, on the first-in, first-out method, or market (net realizable value). Work-in-process and finished goods inventories include materials, labor and manufacturing overhead. See Note 4.
Trade Receivables	(d)          Trade Receivables
	Trade receivables are carried at the original invoice amount less an estimate made for doubtful collection. Management determines the allowance for doubtful accounts on a monthly basis by identifying troubled accounts and by using historical experience applied to an aging of accounts. Trade receivables are written off when deemed uncollectible. Recoveries of trade receivables previously written off are recorded as income when received. A trade receivable is considered to be past due if any portion of the receivable balance is outstanding for more than 30 days. Interest is charged on past due trade receivables. See Note 5.
Property, Plant and Equipment	(e)          Property, Plant and Equipment
	We depreciate property, plant and equipment on the straight-line method by charges to operations in amounts estimated to expense the cost of the assets from the date they are first put into service to the end of the estimated useful lives of the assets. The cost of our building (which was acquired in 1993) and the 2001 and 2007 additions thereto are being depreciated through 2023. We are depreciating the building addition that was completed during the first quarter of 2015 over twenty-five years. Related building improvements are depreciated over ten year periods. Large and durable fixed assets are depreciated over their useful lives that are generally estimated to be five to ten years. Other fixed assets and computer equipment are depreciated over their useful lives that are generally estimated to be five and three years, respectively. See Note 7.
Intangible Assets	(f)          Intangible Assets
	We amortize intangible assets on the straight-line method by charges to operations in amounts estimated to expense the cost of the assets from the date they are first put into service to the end of the estimated useful lives of the assets. In connection with certain credit facilities entered into during the third quarter of 2010, we incurred debt issue costs of $26,489, which costs are being amortized to other expenses, net over the terms of the credit facilities. See Notes 6 and 9.
	We continually assess the realizability of these assets in accordance with the impairment provisions of Codification Topic 360, Accounting for the Impairment or Disposal of Long-Lived Assets. If an impairment review is triggered, we evaluate the carrying value of long-lived assets by determining if impairment exists based on estimated undiscounted future cash flows over the remaining useful life of the assets and comparing that value to the carrying value of the assets. If the carrying value of the asset is greater than the estimated future cash flows, the asset is written down to its estimated fair value. The cash flow estimates that are used contain our best estimates, using appropriate and customary assumptions and projections at the time. We also review the estimated useful life of intangible assets at the end of each reporting period, making any necessary adjustments.
Disclosure of Fair Value of Financial Instruments and Concentration of Risk	(g)          Disclosure of Fair Value of Financial Instruments and Concentration of Risk
	Financial instruments consist mainly of cash, cash equivalents, short-term investments, long-term investments, accounts receivable, accounts payable, bank debt and an interest rate swap. Financial instruments that potentially subject the Company to concentrations of credit risk are principally cash, cash equivalents, short-term investments, long-term investments and accounts receivable. We make short-term and long-term investments in financial instruments that are insured by the FDIC. We account for fair value measurements in accordance with Codification Topic 820, Fair Value Measurements and Disclosures, which defines fair value, establishes a framework for measuring fair value and requires additional disclosures about fair value measurements. The estimated fair value of cash, cash equivalents, short-term investments, long-term investments, accounts receivable and accounts payable approximate their carrying value due to their short maturities. The estimated fair value of bank debt approximates its carrying value because the interest rates are variable. The interest rate swap is carried at fair value. See Note 9.
	Concentration of credit risk with respect to accounts receivable is principally limited to certain customers to whom we make substantial sales. To reduce risk, we routinely assess the financial strength of our customers and, as a consequence, believe that our accounts receivable credit risk exposure is limited. We maintain an allowance for potential credit losses, but historically we have not experienced significant credit losses related to an individual customer or groups of customers in any particular industry or geographic area.
	We believe that supplies and raw materials for the production of our products are available from more than one vendor or farm. Our policy is to maintain more than one source of supply for the components used in our products. However, there is a risk that we could have difficulty in efficiently acquiring essential supplies.
Interest Rate Swap Agreement	(h)          Interest Rate Swap Agreement
	All derivatives are recognized on the balance sheet at their fair value. We entered into an interest rate swap agreement in 2010. On the date the agreement was entered into, we designated the derivative as a hedge of the variability of cash flows to be paid related to our long-term debt. The agreement has been determined to be highly effective in hedging the variability of identified cash flows, so changes in the fair market value of the interest rate swap agreement are recorded as comprehensive (loss) income, until earnings are affected by the variability of cash flows (e.g. when periodic settlements on a variable-rate asset or liability are recorded in earnings). We formally documented the relationship between the interest rate swap agreement and the related hedged items. We also formally assess, both at this interest rate swap agreement’s inception and on an ongoing basis, whether the agreement is highly effective in offsetting changes in cash flow of hedged items. See Note 9.
Revenue Recognition	(i)          Revenue Recognition
	We recognize revenue in accordance with Staff Accounting Bulletin (SAB) No. 104, “Revenue Recognition”, which supersedes SAB No. 101, “Revenue Recognition in Financial Statements”. SAB No. 104 requires that four criteria are met before revenue is recognized. These include i) persuasive evidence that an arrangement exists, ii) delivery has occurred or services have been rendered, iii) the seller’s price is fixed and determinable and iv) collectability is reasonably assured. We recognize revenue at the time of shipment (including to distributors) for substantially all products, as title and risk of loss pass to the customer on delivery to the common carrier after concluding that collectability is reasonably assured. We recognize service revenue at the time the service is performed.
Expense Recognition	(j)          Expense Recognition
	Advertising costs are expensed when incurred, which is generally during the month in which the advertisement is published. Advertising expenses amounted to $29,221 and $18,789 during the three-month periods ended March 31, 2015 and 2014, respectively. All product development expenses are expensed as incurred, as are all related patent costs.
Income Taxes	(k)         Income Taxes
	We account for income taxes in accordance with Codification Topic 740, Income Taxes, which requires that we recognize a current tax liability or asset for current taxes payable or refundable and a deferred tax liability or asset for the estimated future tax effects of temporary differences and carryforwards to the extent they are realizable. We believe it is more likely than not that the deferred tax assets will be realized through future taxable income and future tax effects of temporary differences between book income and taxable income. Accordingly, we have not established a valuation allowance for the deferred tax assets. Codification Topic 740-10 clarifies the accounting for income taxes by prescribing a minimum recognition threshold that a tax position must meet before being recognized in the financial statements. In the ordinary course of business, there are transactions and calculations where the ultimate tax outcome is uncertain. In addition, we are subject to periodic audits and examinations by the Internal Revenue Service and other taxing authorities. We have evaluated the positions taken on our filed tax returns. We have concluded that no uncertain tax positions exist as of March 31, 2015. Although we believe that our estimates are reasonable, actual results could differ from these estimates. See Note 11.
Stock-Based Compensation	(l)          Stock-Based Compensation
	We account for stock-based compensation in accordance with Codification Topic 718, Compensation-Stock Compensation, which generally requires us to recognize non-cash compensation expense for stock-based payments using the fair-value-based method. The fair value of each stock option grant has been estimated on the date of grant using the Black-Scholes option pricing model. Accordingly, we recorded $4,478 and $7,358 of compensation expense pertaining to stock-based compensation, which resulted in a decrease to income before income taxes of less than $0.01 per share during the three-month periods ended March 31, 2015 and 2014, respectively. Codification Topic 718 requires us to reflect gross tax savings resulting from tax deductions in excess of expense reflected in our financial statements as a financing cash flow.
Net Income (Loss) Per Common Share	(m)        Net Income (Loss) Per Common Share
	Net Income (Loss) per common share has been computed in accordance with Codification Topic 260-10, Earnings Per Share. The basic Net Income per share has been computed by dividing Net Income by the weighted average number of common shares outstanding during this period. Diluted Net Income per share has been computed by dividing Net Income by the weighted average number of shares outstanding during the period plus all outstanding stock options with an exercise price that is less than the average market price of the common stock during the period less the number of shares that could have been repurchased at this average market price with the proceeds from the hypothetical stock option exercises. The Net (Loss) per common share in 2014 has been computed by dividing the Net (Loss) by the weighted average number of common shares outstanding during the period, without giving consideration to outstanding stock options because the impact would be anti-dilutive.
		Three-Month Period
		Ended March 31,
		2015		2014
	Weighted average number of shares outstanding		3,027,345		3,026,901
	Effect of dilutive stock options		116,231		0
	Diluted number of shares outstanding		3,143,576		3,026,901
	Outstanding stock options not included in the calculation
	because the effect would be anti-dilutive		4,000		246,000
Use of Estimates	(n)          Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual amounts could differ from those estimates.
New Accounting Pronouncements	(o)          New Accounting Pronouncement
	In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (ASU 2014-09), which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. ASU 2014-09 is effective for the Company on January 1, 2017. Early application is not permitted. ASU 2014-09 permits the use of either the retrospective or cumulative effect transition method. We have evaluated the effect that ASU 2014-09 would have on our financial statements and related disclosures. We expect that ASU 2014-09 will have no significant effect on our ongoing financial reporting, but we continue to evaluate this pending accounting standard.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2015
Summary of Significant Accounting Policies [Abstract]
Schedule of net (loss) income per common share
		Three-Month Period
		Ended March 31,
		2015		2014
	Weighted average number of shares outstanding		3,027,345		3,026,901
	Effect of dilutive stock options		116,231		0
	Diluted number of shares outstanding		3,143,576		3,026,901
	Outstanding stock options not included in the calculation
	because the effect would be anti-dilutive		4,000		246,000

Cash_Cash_Equivalents_ShortTer1

Cash, Cash Equivalents, Short-Term Investments and Long-Term Investments (Tables)	3 Months Ended
	Mar. 31, 2015
Cash, Cash Equivalents, Short-Term Investments and Long-Term Investments [Abstract]
Schedule of Cash, Cash Equivalents and Short-term Investments		As of		As of		Increase
		31-Mar-15		December 31, 2014		(Decrease)
	Cash and cash equivalents	$	2,470,088	$	850,028	$	1,620,060
	Short-term investments		1,740,000		2,489,000		(749,000	)
	Subtotal		4,210,088		3,339,028		871,060
	Long-term investments		0		496,000		(496,000	)
	Total	$	4,210,088	$	3,835,028	$	375,060

Inventory_Tables

Inventory (Tables)	3 Months Ended
	Mar. 31, 2015
Inventory [Abstract]
Schedule of Inventory, Current		As of		As of		Increase
		31-Mar-15		December 31, 2014		(Decrease)
	Raw materials	$	314,317	$	306,444	$	7,873
	Work-in-process		221,645		355,745		(134,100	)
	Finished goods		42,701		283,566		(240,865	)
	Total	$	578,663	$	945,755	($	367,092	)

Accounts_Receivable_Tables

Accounts Receivable (Tables)	3 Months Ended
	Mar. 31, 2015
Accounts Receivable[Abstract]
Schedule of Accounts, Notes, Loans and Financing Receivable		As of			As of			(Decrease)
		31-Mar-15			December 31, 2014
	Trade accounts receivable, gross	$	755,221		$	1,004,990		($	249,769	)
	Accumulated allowance for bad debt and product returns		(16,637	)		(16,194	)		(443	)
	Trade accounts receivable, net		738,584			988,796			(250,212	)
	Other receivables		16,270			16,496			(226	)
	Accounts receivable, net	$	754,854		$	1,005,292		($	250,438	)

Prepaid_Expenses_and_Other_Ass1

Prepaid Expenses and Other Assets (Tables)	3 Months Ended
	Mar. 31, 2015
Prepaid Expenses and Other Assets [Abstract]
Schedule of Prepaid expenses and other assets		As of			As of			Increase
		31-Mar-15			December 31, 2014			(Decrease)
	Prepaid expenses and other assets	$	163,341		$	133,119		$	30,222
	Security deposits		15,280			15,280			0
	Current subtotal		178,621			148,399			30,222
	Debt issue costs		26,489			26,489			0
	Accumulated amortization of debt issue costs		(17,199	)		(16,479	)		(720	)
	Security deposits		8,920			8,920			0
	Long-term subtotal		18,210			18,930			(720	)
	Total	$	196,831		$	167,329		$	29,502

Property_Plant_And_Equipment_T

Property, Plant And Equipment (Tables)	3 Months Ended
	Mar. 31, 2015
Property, Plant and Equipment [Abstract]
Schedule of property, plant and equipment		As of			As of			Increase
		31-Mar-15			December 31, 2014			(Decrease)
	Laboratory and manufacturing equipment	$	3,598,697		$	3,522,465		$	76,232
	Building and improvements		4,418,964			2,969,891			1,449,073
	Office furniture and equipment		475,147			470,607			4,540
	Construction in progress(1)		530,526			1,270,672			(740,146	)
	Land		50,000			50,000			0
	Property, plant and equipment, gross		9,073,334			8,283,635			789,699
	Accumulated depreciation		(4,514,738	)		(4,445,988	)		(68,750	)
	Property, plant and equipment, net	$	4,558,596		$	3,837,647		$	720,949
	(1) As of December 31, 2014, construction in progress consisted of a building addition that was completed during the first quarter of 2015. As of March 31, 2015, construction in progress consisted principally of payments towards new manufacturing equipment.

Accounts_Payable_and_Accrued_E1

Accounts Payable and Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2015
Accounts Payable and Accrued Expenses [Abstract]
Schedule of accounts payable and expenses		As of		As of		(Decrease)
		31-Mar-15		December 31, 2014
	Accounts payable – capital	$	99,795	$	251,383	($	151,588	)
	Accounts payable – trade		203,972		204,810		(838	)
	Accrued payroll		124,867		145,176		(20,309	)
	Accrued clinical studies		68,428		131,945		(63,517	)
	Accrued professional fees		32,737		42,250		(9,513	)
	Accrued other		57,387		76,113		(18,726	)
	Total	$	587,186	$	851,677	($	264,491	)

Bank_Debt_Tables

Bank Debt (Tables)	3 Months Ended
	Mar. 31, 2015
Bank Debt [Abstract]
Schedule of principal payments due	Period	$1,000,000		$600,000		Total
		mortgage		note
	Nine months ending December 31, 2015	$	40,799	$	60,526	$	101,325
	Year ending December 31, 2016		57,384		0		57,384
	Year ending December 31, 2017		61,056		0		61,056
	Year ending December 31, 2018		64,876		0		64,876
	Year ending December 31, 2019		68,908		0		68,908
	After December 31, 2019		493,696		0		493,696
	Total	$	786,719	$	60,526	$	847,245

Other_ExpensesNet_Tables

Other Expenses,Net (Tables)	3 Months Ended
	Mar. 31, 2015
Other Expenses, Net [Abstract]
Schedule of other expenses, net		Three-Month Periods
		Ended March 31,
		2015			2014
	Interest income	($	2,982	)	($	3,954	)
	Interest expense		13,071			14,962
	Debt issuance amortization		720			719
	Other (gains)		(5,359	)		(320	)
	Other expenses, net	$	5,450		$	11,407

Segment_and_Significant_Custom1

Segment and Significant Customer Information (Tables)	3 Months Ended
	Mar. 31, 2015
Segment and Significant Customer Information [Abstract]
Schedule of sales to significant customers
		Three-Month Periods Ended March 31,
		2015			2014
	Animal Health International, Inc.(1)		42	%		38	%
	MWI Veterinary Supply Company(2)		26	%		23	%
Schedule of accounts receivable due from significant customers		As of			As of
		31-Mar-15			31-Dec-14
	Animal Health International, Inc.(1)		40	%		45	%
	MWI Veterinary Supply Company(2)		28	%		26	%
	(1) During May 2015, Patterson Companies, Inc. (NASDAQ: PDCO) announced its intent to aquire Animal Health International, Inc.
	(2) During March 2015, AmerisourceBergen Corporation (NYSE: ABC) acquired MWI Veterinary Supply Company.

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Details)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Net (Loss) Income Per Common Share
Weighted average number of shares outstanding	3,027,345	3,026,901
Effect of dilutive stock options	116,231	0
Diluted number of shares outstanding	3,143,576	3,026,901
Outstanding stock options not included in the calculation because the effect would be anti-dilutive	4,000	246,000

Summary_of_Significant_Account4

Summary of Significant Accounting Policies (Details Textual) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Significant Accounting Policies Textual [Abstract]
Decrease (increase) in income (loss) before income taxes descripton	Less than $0.01	Less than $0.01
Stock-based compensation	$4,478	$7,358
Advertising expense	29,221	18,789
Federal deposit insurance corporation limits	250,000
Debt issue costs	26,489
U.S. government aggregated amount	$1,969,788		$566,637
Building Addition [Member]
Significant Accounting Policies Textual [Abstract]
Property, plant and equipment, useful life	25 years
Building Improvements [Member]
Significant Accounting Policies Textual [Abstract]
Property, plant and equipment, useful life	10 years
Property, Plant and Equipment, Other Types [Member] | Minimum [Member]
Significant Accounting Policies Textual [Abstract]
Property, plant and equipment, useful life	5 years
Property, Plant and Equipment, Other Types [Member] | Maximum [Member]
Significant Accounting Policies Textual [Abstract]
Property, plant and equipment, useful life	10 years
Computer Equipment [Member]
Significant Accounting Policies Textual [Abstract]
Property, plant and equipment, useful life	3 years
Other Assets [Member]
Significant Accounting Policies Textual [Abstract]
Property, plant and equipment, useful life	5 years

Cash_Cash_Equivalents_ShortTer2

Cash, Cash Equivalents, Short-Term Investments and Long-Term Investments (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Cash, Cash Equivalents, Short-Term Investments and Long-Term Investments [Abstract]
Cash and cash equivalents	$2,470,088	$2,239,731	$850,028	$2,270,385
Short-term investments	1,740,000		2,489,000
Subtotal	4,210,088		3,339,028
Long-term investments	0		496,000
Total	4,210,088		3,835,028
Increase (Decrease) in cash and cash equivalents	1,620,060	-30,654
Increase (Decrease) in short-term investments	-749,000
Increase (Decrease) in cash and cash equivalents and short term investments	871,060
Increase (Decrease) in long term investments	-496,000
Increase (Decrease) in cash and cash equivalents short term and long term investments	$375,060

Inventory_Details

Inventory (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Inventory [Abstract]
Raw materials	$314,317		$306,444
Work-in-process	221,645		355,745
Finished goods	42,701		283,566
Total	578,663		945,755
Increase (Decrease) in Raw materials inventories	7,873
Increase (Decrease) in Work-in-process inventories	-134,100
Increase (Decrease) in Finished goods inventories	-240,865
Increase (Decrease) in inventories	($367,092)	($259,183)

Accounts_Receivable_Details

Accounts Receivable (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Accounts Receivable[Abstract]
Trade accounts receivable, gross	$755,221		$1,004,990
Accumulated allowance for bad debt and product returns	-16,637		-16,194
Trade accounts receivable, net	738,584		988,796
Other receivables	16,270		16,496
Accounts receivable, net	754,854		1,005,292
(Decrease) in Trade accounts receivable, gross	-249,769
(Decrease) in Accumulated allowance for bad debt and product returns	-443
(Decrease) in Trade accounts receivable, net	-250,212
(Decrease) in Other receivables	-226
(Decrease) in Accounts receivable, net	($250,438)	$88,616

Prepaid_Expenses_and_Other_Ass2

Prepaid Expenses and Other Assets (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Prepaid Expenses and Other Assets [Abstract]
Prepaid expenses and other assets	$163,341	$133,119
Security deposits	15,280	15,280
Current subtotal	178,621	148,399
Debt issue costs	26,489	26,489
Accumulated amortization of debt issue costs	-17,199	-16,479
Security deposits	8,920	8,920
Long-term subtotal	18,210	18,930
Total	196,831	167,329
Increase (Decrease) in Prepaid expenses and other assets	30,222
Increase (Decrease) in Security deposits	0
Increase (Decrease) in Current subtotal	30,222
Increase (Decrease) in Debt issue costs	0
Increase (Decrease) in Accumulated amortization of debt issue costs	-720
Increase (Decrease) in Security deposits	0
Increase (Decrease) in Long-term subtotal	-720
Increase (Decrease) in Prepaid expenses and other assets, Total	$29,502

Property_Plant_And_Equipment_D

Property, Plant And Equipment (Details) (USD $)	3 Months Ended
	Mar. 31, 2015		Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Laboratory and manufacturing equipment	$3,598,697		$3,522,465
Building and improvements	4,418,964		2,969,891
Office furniture and equipment	475,147		470,607
Construction in progress	530,526	[1]	1,270,672	[1]
Land	50,000		50,000
Property, plant and equipment, gross	9,073,334		8,283,635
Accumulated depreciation	-4,514,738		-4,445,988
Property, plant and equipment, net	4,558,596		3,837,647
Property, plant and equipment, gross increase (decrease)	789,699
Less: accumulated depreciation (increase)	-68,750
Property, plant and equipment, net increase	720,949
Laboratory and manufacturing equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross increase (decrease)	76,232
Building and improvements [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross increase (decrease)	1,449,073
Office furniture and equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross increase (decrease)	4,540
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross increase (decrease)	-740,146	[1]
Land [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross increase (decrease)	$0
[1]	As of December 31, 2014, construction in progress consisted of a building addition that was completed during the first quarter of 2015. As of March 31, 2015, construction in progress consisted principally of payments towards new manufacturing equipment.

Accounts_Payable_and_Accrued_E2

Accounts Payable and Accrued Expenses (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Accounts Payable and Accrued Expenses [Abstract]
Accounts payable - capital	$99,795	$251,383
Accounts payable - trade	203,972	204,810
Accrued payroll	124,867	145,176
Accrued clinical studies	68,428	131,945
Accrued professional fees	32,737	42,250
Accrued other	57,387	76,113
Total	587,186	851,677
(Decrease) in accounts payable - capital	-151,588
(Decrease) in accounts payable - trade	-838
(Decrease) in accrued payroll	-20,309
(Decrease) in accrued clinical studies	-63,517
(Decrease) in accrued professional fees	-9,513
(Decrease) in accrued other	-18,726
(Decrease) in accounts payable and accrued liabilities	($264,491)

Bank_Debt_Details

Bank Debt (Details) (USD $)	Mar. 31, 2015
Debt Instrument [Line Items]
Nine months ending December 31, 2015	$101,325
Year ending December 31, 2016	57,384
Year ending December 31, 2017	61,056
Year ending December 31, 2018	64,876
Year ending December 31, 2019	68,908
After December 31, 2019	493,696
Total	847,245
$1,000,000 mortgage [Member]
Debt Instrument [Line Items]
Nine months ending December 31, 2015	40,799
Year ending December 31, 2016	57,384
Year ending December 31, 2017	61,056
Year ending December 31, 2018	64,876
Year ending December 31, 2019	68,908
After December 31, 2019	493,696
Total	786,719
600,000 note [Member]
Debt Instrument [Line Items]
Nine months ending December 31, 2015	60,526
Year ending December 31, 2016	0
Year ending December 31, 2017	0
Year ending December 31, 2018	0
Year ending December 31, 2019	0
After December 31, 2019	0
Total	$60,526

Bank_Debt_Details_Textual

Bank Debt (Details Textual) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2011	Sep. 30, 2010
Debt Instrument [Line Items]
Secured Debt				$2,100,000
Proceeds from Notes Payable			600,000
Derivatives Interest Rate Swap Payments	5,219	5,566
Other Comprehensive Income (Loss), Net Of Tax	-3,906	-1,408
Line of credit facility, description	a wholly owned subsidiary of TD Financial Group, which is a multinational bank with approximately $944 billion in assets and over 22 million clients worldwide
Interest Rate Swap [Member]
Debt Instrument [Line Items]
Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate	3.43%			6.04%
Derivative, Notional Amount	786,719			1,000,000
Debt Instrument, Description of Variable Rate Basis	London Interbank Offered Rate (LIBOR) of 3.43
Mortgages [Member]
Debt Instrument [Line Items]
Secured Debt				1,000,000
Debt Instrument, Maturity Date, Description				ten-year
Mortgage Loans on Real Estate, Periodic Payment Terms, Balloon Payment to be Received				451,885
Mortgage Loans on Real Estate, Periodic Payment Terms				will be due in the third quarter of 2020
Note Payable [Member]
Debt Instrument [Line Items]
Secured Debt				600,000
Debt Instrument, Maturity Date, Description				fifty-four month
Debt Instrument, Description of Variable Rate Basis	Interest on the note is variable at the higher of 4.25% per annum or the LIBOR plus 3.25% per annum
Line Of Credit [Member]
Debt Instrument [Line Items]
Secured Debt				$500,000
Debt Instrument, Maturity Date, Description	The $500,000 line of credit is available as needed and has been extended through May 31, 2016 and is renewable annually thereafter.
Debt Instrument, Description of Variable Rate Basis	Interest on any borrowings against the line of credit would be variable at the higher of 4.25% per annum or the LIBOR plus 3.5% per annum

Other_ExpensesNet_Details

Other Expenses,Net (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Other Expenses, Net [Abstract]
Interest income	($2,982)	($3,954)
Interest expense	13,071	14,962
Debt issuance amortization	720	719
Other (gains)	-5,359	-320
Other expenses, net	$5,450	$11,407

Income_Taxes_Details

Income Taxes (Details) (USD $)	3 Months Ended			12 Months Ended	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2013	Dec. 31, 2014	Dec. 31, 2004
Income Tax [Textual]
Income tax expense	$335,520	$14,489
Income tax rate percenatge	41.00%	1.26%
Finite-Lived intangible assets, remaining amortization period	15 years
Investment	820,000		65,000	755,000
Intangible asset [Member]
Income Tax [Textual]
License costs					965,000
Investment [Member]
Income Tax [Textual]
Investment	1,112,000
State and Local Jurisdiction [Member]
Income Tax [Textual]
State net operating loss carryforward				1,858,000
Tax credit carryforward, description				2028 through 2031
Domestic Tax Authority [Member]
Income Tax [Textual]
Federal net operating loss carryforward				$1,368,000
Tax credit carryforward, description				2029 through 2031

Commitments_and_Contingent_Lia1

Commitments and Contingent Liabilities (Details) (USD $)	Mar. 31, 2015
Commitments and Contingent Liabilities [Abstract]
Obligations for production of inventory	$766,794
Other obligations	$66,988

Segment_and_Significant_Custom2

Segment and Significant Customer Information (Details)	3 Months Ended
	Mar. 31, 2015		Mar. 31, 2014
Animal Health International, Inc [Member]
Revenue, Major Customer [Line Items]
Concentration Risk, Percentage	42.00%	[1]	38.00%	[1]
MWI Veterinary Supply Company [Member]
Revenue, Major Customer [Line Items]
Concentration Risk, Percentage	26.00%	[2]	23.00%	[2]
[1]	During May 2015, Patterson Companies, Inc. (NASDAQ: PDCO) announced its intent to aquire Animal Health International, Inc.
[2]	During March 2015, AmerisourceBergen Corporation (NYSE: ABC) acquired MWI Veterinary Supply Company.

Segment_and_Significant_Custom3

Segment and Significant Customer Information (Details 1)	Mar. 31, 2015		Dec. 31, 2014
Animal Health International, Inc [Member]
Revenue, Major Customer [Line Items]
Accounts receivable due from significant customers	40.00%	[1]	45.00%	[1]
MWI Veterinary Supply Company [Member]
Revenue, Major Customer [Line Items]
Accounts receivable due from significant customers	28.00%	[2]	26.00%	[2]
[1]	During May 2015, Patterson Companies, Inc. (NASDAQ: PDCO) announced its intent to aquire Animal Health International, Inc.
[2]	During March 2015, AmerisourceBergen Corporation (NYSE: ABC) acquired MWI Veterinary Supply Company.

Segment_and_Significant_Custom4

Segment and Significant Customer Information (Details Textual) (Sales Revenue, Net [Member])	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Revenue, Major Customer [Line Items]
Concentration Risk, Percentage	10.00%
Primary dairy and beef industries [Member]
Revenue, Major Customer [Line Items]
Concentration Risk, Percentage	83.00%	79.00%
Foreign dairy and beef industries [Member]
Revenue, Major Customer [Line Items]
Concentration Risk, Percentage	16.00%	14.00%

Related_Party_Transactions_Det

Related Party Transactions (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Related Party Transactions [Textual]
Revenues from transactions with related party	$192,642	$125,768
Accounts receivable, related parties	31,226		18,796
Related party transaction, expenses from transactions with related party	$1,272	$4,405

Employee_Benefits_Details

Employee Benefits (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Share Based Compensation [Textual ]
Employee Savings Plan Description	One month
Defined Benefit Plans, General Information	August 2012 we have matched 100% of the first 3% of each employee's salary that is contributed to the Plan and 50% of the next 2% of each employee's salary that is contributed to the Plan.
Defined Benefit Plan, Benefits Paid	$16,726	$16,167

Subsequent_Events_Details

Subsequent Events (Details) (Subsequent Event [Member])	Apr. 30, 2015
Subsequent Event [Member]
Subsequent Events [Textual]
Equity method investment ownership percentage	20.00%